CN101041076B - 控释软膏组合基质及其制备方法 - Google Patents
控释软膏组合基质及其制备方法 Download PDFInfo
- Publication number
- CN101041076B CN101041076B CN2007100111964A CN200710011196A CN101041076B CN 101041076 B CN101041076 B CN 101041076B CN 2007100111964 A CN2007100111964 A CN 2007100111964A CN 200710011196 A CN200710011196 A CN 200710011196A CN 101041076 B CN101041076 B CN 101041076B
- Authority
- CN
- China
- Prior art keywords
- minutes
- stroma
- beta
- release
- schardinger dextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002674 ointment Substances 0.000 title claims description 38
- 150000001875 compounds Chemical class 0.000 title claims description 17
- 238000000034 method Methods 0.000 title abstract description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 68
- 239000003814 drug Substances 0.000 claims abstract description 40
- 235000019325 ethyl cellulose Nutrition 0.000 claims abstract description 29
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 235000011187 glycerol Nutrition 0.000 claims abstract description 23
- 229940079593 drug Drugs 0.000 claims abstract description 22
- WTJXVDPDEQKTCV-UHFFFAOYSA-N 4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2C1CC1C(N(C)C)C(=O)C(C(N)=O)=C(O)C1(O)C2=O WTJXVDPDEQKTCV-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229960002421 minocycline hydrochloride Drugs 0.000 claims abstract description 7
- 238000000227 grinding Methods 0.000 claims description 38
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 32
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims description 28
- 229920001249 ethyl cellulose Polymers 0.000 claims description 28
- 239000001856 Ethyl cellulose Substances 0.000 claims description 23
- 239000004570 mortar (masonry) Substances 0.000 claims description 21
- 238000010438 heat treatment Methods 0.000 claims description 17
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 9
- 229960000282 metronidazole Drugs 0.000 claims description 6
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical group CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 6
- 229960000723 ampicillin Drugs 0.000 claims description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 4
- IPWKIXLWTCNBKN-UHFFFAOYSA-N Madelen Chemical compound CC1=NC=C([N+]([O-])=O)N1CC(O)CCl IPWKIXLWTCNBKN-UHFFFAOYSA-N 0.000 claims description 3
- 229960002313 ornidazole Drugs 0.000 claims description 3
- 229920000858 Cyclodextrin Polymers 0.000 abstract description 20
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract description 19
- 239000004925 Acrylic resin Substances 0.000 abstract description 14
- 229920000178 Acrylic resin Polymers 0.000 abstract description 13
- 239000000463 material Substances 0.000 abstract description 4
- 229920002521 macromolecule Polymers 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 208000030194 mouth disease Diseases 0.000 abstract 1
- 125000003367 polycyclic group Chemical group 0.000 abstract 1
- 238000007613 slurry method Methods 0.000 abstract 1
- 208000013464 vaginal disease Diseases 0.000 abstract 1
- 239000000758 substrate Substances 0.000 description 22
- 230000008018 melting Effects 0.000 description 15
- 238000002844 melting Methods 0.000 description 15
- 239000008029 phthalate plasticizer Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000005304 joining Methods 0.000 description 11
- 239000004014 plasticizer Substances 0.000 description 11
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 5
- 229960001200 clindamycin hydrochloride Drugs 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 4
- 229960002152 chlorhexidine acetate Drugs 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 description 4
- PTNZGHXUZDHMIQ-UHFFFAOYSA-N 4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2C(C)C(C(O)C3C(C(O)=C(C(N)=O)C(=O)C3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-UHFFFAOYSA-N 0.000 description 3
- 229920003163 Eudragit® NE 30 D Polymers 0.000 description 3
- 241001597008 Nomeidae Species 0.000 description 3
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 3
- 229960004082 doxycycline hydrochloride Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003883 ointment base Substances 0.000 description 3
- 229960005053 tinidazole Drugs 0.000 description 3
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 2
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 2
- IPKKHRVROFYTEK-UHFFFAOYSA-N dipentyl phthalate Chemical compound CCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCC IPKKHRVROFYTEK-UHFFFAOYSA-N 0.000 description 2
- MQHNKCZKNAJROC-UHFFFAOYSA-N dipropyl phthalate Chemical compound CCCOC(=O)C1=CC=CC=C1C(=O)OCCC MQHNKCZKNAJROC-UHFFFAOYSA-N 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 2
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 238000005498 polishing Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LNSXRXFBSDRILE-UHFFFAOYSA-N Cucurbitacin Natural products CC(=O)OC(C)(C)C=CC(=O)C(C)(O)C1C(O)CC2(C)C3CC=C4C(C)(C)C(O)C(O)CC4(C)C3(C)C(=O)CC12C LNSXRXFBSDRILE-UHFFFAOYSA-N 0.000 description 1
- CVKKIVYBGGDJCR-SXDZHWHFSA-N Cucurbitacin B Natural products CC(=O)OC(C)(C)C=CC(=O)[C@@](C)(O)[C@@H]1[C@@H](O)C[C@]2(C)C3=CC[C@@H]4C(C)(C)C(=O)[C@H](O)C[C@@]4(C)[C@@H]3CC(=O)[C@@]12C CVKKIVYBGGDJCR-SXDZHWHFSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- 244000153234 Hibiscus abelmoschus Species 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- 150000001904 cucurbitacins Chemical class 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- PIGAXYFCLPQWOD-UHFFFAOYSA-N dihydrocucurbitacin I Natural products CC12C(=O)CC3(C)C(C(C)(O)C(=O)CCC(C)(O)C)C(O)CC3(C)C1CC=C1C2C=C(O)C(=O)C1(C)C PIGAXYFCLPQWOD-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100111964A CN101041076B (zh) | 2007-04-27 | 2007-04-27 | 控释软膏组合基质及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100111964A CN101041076B (zh) | 2007-04-27 | 2007-04-27 | 控释软膏组合基质及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101041076A CN101041076A (zh) | 2007-09-26 |
CN101041076B true CN101041076B (zh) | 2010-08-25 |
Family
ID=38807006
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007100111964A Expired - Fee Related CN101041076B (zh) | 2007-04-27 | 2007-04-27 | 控释软膏组合基质及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101041076B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102488653A (zh) * | 2011-12-15 | 2012-06-13 | 哈药集团中药二厂 | 治疗牙周炎的药物 |
CN103405780B (zh) * | 2013-08-26 | 2015-06-24 | 江苏知原药业有限公司 | 一种含维a酸包合物及丙酸氯倍他索软膏剂及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1559406A (zh) * | 2004-02-24 | 2005-01-05 | 北京阜康仁生物制药科技有限公司 | 抗滴虫、抗厌氧菌化合物替硝唑的一组药物制剂 |
CN1613452A (zh) * | 2003-11-07 | 2005-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 美洛昔康与β-环糊精或其衍生物复合物结肠定位释放制剂 |
CN1660118A (zh) * | 2004-12-23 | 2005-08-31 | 鲁南制药股份有限公司 | 含有非那雄胺与环糊精或其衍生物的药物组合物 |
-
2007
- 2007-04-27 CN CN2007100111964A patent/CN101041076B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1613452A (zh) * | 2003-11-07 | 2005-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 美洛昔康与β-环糊精或其衍生物复合物结肠定位释放制剂 |
CN1559406A (zh) * | 2004-02-24 | 2005-01-05 | 北京阜康仁生物制药科技有限公司 | 抗滴虫、抗厌氧菌化合物替硝唑的一组药物制剂 |
CN1660118A (zh) * | 2004-12-23 | 2005-08-31 | 鲁南制药股份有限公司 | 含有非那雄胺与环糊精或其衍生物的药物组合物 |
Non-Patent Citations (1)
Title |
---|
CN 1559406 A,全文. |
Also Published As
Publication number | Publication date |
---|---|
CN101041076A (zh) | 2007-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102387789A (zh) | 含有无定形cddo-me的延迟释放口服组合物 | |
WO1988006457A1 (en) | Medicinal composition containing albumin as carrier and process for its preparation | |
US20110250269A1 (en) | Highly efficient and long-acting slow-release formulation of poorly soluble drugs and preparation method thereof | |
MX2007005427A (es) | Composicion de dispersion solida de pranlukast con biodisponibilidad mejorada y metodo para preparar la dispersion solida. | |
CN105640913B (zh) | 一种奥美沙坦酯片及其制备方法 | |
CN112040984A (zh) | 药物制剂、制备药物制剂的方法和包含其的药物 | |
CN108478785A (zh) | 一种口服胰岛素胶束纳米粒及其制备方法 | |
CN101041076B (zh) | 控释软膏组合基质及其制备方法 | |
CN101020060A (zh) | 恩替卡韦的环糊精包合物及其制备方法和药物应用 | |
CN108853042A (zh) | 一种米氮平冻干口崩片及其制备方法和应用 | |
CN101623269A (zh) | 口服缓释给药的颗粒 | |
CN106361724A (zh) | 一种20(R)-人参皂苷Rg3缓释纳米微球组合及其制备方法 | |
CN109646417B (zh) | 一种曲美他嗪缓释片及其制备方法 | |
CN102266309A (zh) | 一种新型罗红霉素胶囊及其制备方法 | |
CN103845332B (zh) | 一种达沙替尼药用组合物及其制备方法 | |
CN108785260A (zh) | 温敏性非甾体抗炎药固体分散体和速溶片及其制备方法 | |
CN101023948A (zh) | 利莫那班或其可药用盐的环糊精包合物及其制备方法和药物应用 | |
CN101716135B (zh) | 大豆异黄酮固体分散体栓剂及其制备方法 | |
CN104208072A (zh) | 一种醋酸甲地孕酮热熔挤出制剂 | |
CN104367547B (zh) | 一种适用于口腔给药的缓控释替硝唑软膏 | |
CN102552205B (zh) | 一种枸橼酸钾控释片制剂及其制备方法 | |
CN106821961B (zh) | 一种热熔挤压制备奥拉西坦口腔膜剂的方法 | |
CN102526111A (zh) | 一种含有蟾酥脂溶物的缓释微球及其制备方法与应用 | |
CN102258496A (zh) | 溴吡斯的明缓释片剂及其制备方法 | |
CN108379227B (zh) | 一种包载芦丁的聚合物胶束及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING ENZEMEI TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: DALIAN UNIVERSITY OF TECHNOLOGY Effective date: 20120420 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 116024 DALIAN, LIAONING PROVINCE TO: 100086 HAIDIAN, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120420 Address after: 100086 Beijing city Haidian District Qingyun in Garden District No. 9 Fullhouse Tsing Wun contemporary building 17 layer 1705G3 Patentee after: Beijing Enze Technology Co., Ltd. Address before: 116024 Ganjingzi City, Dalian province Dalian District Ling Road, No. 2, No. Patentee before: Dalian University of Technology |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100825 Termination date: 20170427 |
|
CF01 | Termination of patent right due to non-payment of annual fee |